journal article·2021-07-21

Shuttle-Shape Carrier-Free Platinum-Coordinated Nanoreactors with O2 Self-Supply and ROS Augment for Enhanced Phototherapy of Hypoxic Tumor

Xu Fu, Wen Yin, Dao Shi, Yifan Yang, Suisui He, Jun Hai, Zhenqing Hou, Zhongxiong Fan, Dekui Zhang

ACS Applied Materials & Interfaces· Volume 13· Issue 28
Publisher page

Abstract

The synergistic nanotheranostics of reactive oxygen species (ROS) augment or phototherapy has been a promising method within synergistic oncotherapy. However, it is still hindered by sophisticated design and fabrication, lack of a multimodal synergistic effect, and hypoxia-associated poor photodynamic therapy (PDT) efficacy. Herein, a kind of porous shuttle-shape platinum (IV) methylene blue (Mb) coordination polymer nanotheranostics-loaded 10-hydroxycamptothecin (CPT) is fabricated to address the abovementioned limitations. Our nanoreactors possess spatiotemporally controlled O2 self-supply, self-sufficient singlet oxygen (1O2), and outstanding photothermal effect. Once they are taken up by tumor cells, nanoreactors as a cascade catalyst can efficiently catalyze degradation of the endogenous hydrogen peroxide (H2O2) into O2 to alleviate tumor hypoxia. The production of O2 can ensure enhanced PDT. Subsequently, under both stimuli of external red light irradiation and internal lysosomal acidity, nanoreactors can achieve the on-demand release of CPT to augment in situ mitochondrial ROS and highly efficient tumor ablation via phototherapy. Moreover, under the guidance of near-infrared (NIR) fluorescent imaging, our nanoreactors exhibit strongly synergistic potency for treatment of hypoxic tumors while reducing damages against normal tissues and organs. Collectively, shuttle-shape platinum-coordinated nanoreactors with augmented ROS capacity and enhanced phototherapy efficiency can be regarded as a novel tumor theranostic agent and further promote the research of synergistic oncotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomaterials, College of Materials, Research Center of Biomedical Engineering of Xiamen & Key Laboratory of Biomedical Engineering of Fujian Province & Fujian Provincial Key Laboratory for Soft Functional Materials Research, Xiamen University, Xiamen 361005, China

State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, Lanzhou University, Lanzhou 730000, Gansu, China

Funding

Ministry of Education of the People's Republic of China · National Natural Science Foundation of China · Natural Science Foundation of Gansu Province · Lanzhou University Second Hospital

References (43)

Show source-provided references
1. 10.1016/j.biomaterials.2016.11.05610.1016/j.biomaterials.2016.11.056 ↗
2. 10.1038/s41467-019-09566-310.1038/s41467-019-09566-3 ↗
3. 10.1126/science.aaw985510.1126/science.aaw9855 ↗
4. 10.1021/acs.biochem.9b0085710.1021/acs.biochem.9b00857 ↗
5. 10.1021/acsami.9b0105710.1021/acsami.9b01057 ↗
6. 10.1038/nature1739910.1038/nature17399 ↗
7. 10.1016/j.cell.2015.10.00110.1016/j.cell.2015.10.001 ↗
8. 10.1021/acs.bioconjchem.0c0047010.1021/acs.bioconjchem.0c00470 ↗
9. 10.1021/jacs.0c0902910.1021/jacs.0c09029 ↗
10. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
11. 10.1002/adfm.20200591810.1002/adfm.202005918 ↗
12. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
13. 10.1021/acsnano.8b0610410.1021/acsnano.8b06104 ↗
14. 10.1021/jacs.8b0772710.1021/jacs.8b07727 ↗
15. 10.1021/acsami.0c0097010.1021/acsami.0c00970 ↗
16. 10.1002/adfm.20180558210.1002/adfm.201805582 ↗
17. 10.1039/D0SC02387F10.1039/D0SC02387F ↗
18. 10.1021/acs.molpharmaceut.9b0011910.1021/acs.molpharmaceut.9b00119 ↗
19. 10.1021/acsami.0c1068510.1021/acsami.0c10685 ↗
20. 10.1021/ja508679h10.1021/ja508679h ↗
21. 10.1021/acs.chemrev.6b0052510.1021/acs.chemrev.6b00525 ↗
22. 10.1021/acsami.9b1693410.1021/acsami.9b16934 ↗
23. 10.1021/acsnano.0c0549910.1021/acsnano.0c05499 ↗
24. 10.1016/j.actbio.2020.04.05210.1016/j.actbio.2020.04.052 ↗
25. 10.1021/acsnano.7b0306210.1021/acsnano.7b03062 ↗
26. 10.1016/j.jconrel.2017.05.01110.1016/j.jconrel.2017.05.011 ↗
27. 10.1002/advs.20180015510.1002/advs.201800155 ↗
28. 10.1016/j.biomaterials.2020.12055710.1016/j.biomaterials.2020.120557 ↗
29. 10.1016/j.dyepig.2019.10792210.1016/j.dyepig.2019.107922 ↗
30. 10.1021/acsnano.9b0542510.1021/acsnano.9b05425 ↗
31. 10.1021/jacs.0c0702210.1021/jacs.0c07022 ↗
32. 10.1016/j.cej.2019.12242610.1016/j.cej.2019.122426 ↗
33. 10.1126/science.aaa620410.1126/science.aaa6204 ↗
34. 10.1039/C8CS00304A10.1039/C8CS00304A ↗
35. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
36. 10.1021/acsnano.8b0785210.1021/acsnano.8b07852 ↗
37. 10.1021/acs.langmuir.5b0203910.1021/acs.langmuir.5b02039 ↗
38. 10.1021/jacs.0c1009810.1021/jacs.0c10098 ↗
39. 10.1002/adfm.20190771610.1002/adfm.201907716 ↗
40. 10.1021/acs.molpharmaceut.0c0016510.1021/acs.molpharmaceut.0c00165 ↗
41. 10.1021/jacs.6b0945110.1021/jacs.6b09451 ↗
42. 10.1021/mp500464b10.1021/mp500464b ↗
43. 10.1021/acsami.5b0734810.1021/acsami.5b07348 ↗